Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia

0
0 / 5 (0 votos)

The Lancet Hematology

Published: 15 November 2017

DOI: http://dx.doi.org/10.1016/S2352-3026(17)30211-9

Manuela Aguilar-Guisado, PhD, Ildefonso Espigado, PhD, Almudena Martín-Peña, PhD, Carlota Gudiol, PhD, Cristina Royo-Cebrecos, MD, José Falantes, MD, Lourdes Vázquez-López, MD, María Isabel Montero, PhD, Clara Rosso-Fernández, PhD, María de la Luz Martino, MD, Rocío Parody, PhD, José González-Campos, PhD, Sebastián Garzón-López, MD, Cristina Calderón-Cabrera, MD, Pere Barba, MD, Nancy Rodríguez, MD, Montserrat Rovira, PhD, Enrique Montero-Mateos, MD, Jordi Carratalá, PhD, Prof José Antonio Pérez-Simón, PhD, José Miguel Cisneros, PhD

Background: Continuation of empirical antimicrobial therapy (EAT) for febrile neutropenia in patients with haematological malignancies until neutrophil recovery could prolong the therapy unnecessarily. We aimed to establish whether EAT discontinuation driven by a clinical approach regardless of neutrophil recovery would optimise the duration of therapy.
 

SEGUIR LEYENDO